Research Shows That Ketamine Delivers Quickly For Treatment-Resistant Depression

In the biggest clinical trial to date testing this drug, the anesthetic ketamine delivered big and quickly to patients with treatment-resistant depression.

Researchers from the Icahn School of Medicine at Mount Sinai carried out the study, testing the drug in patients with major depressive disorder. They found that not only was it effective, but it delivered results in one day – significantly shorter than conventional antidepressants, which often require more than a week to begin to work.

Investigators evaluated 72 people diagnosed with treatment-resistant depression (defined as depression that persists after at least two drug interventions). These patients were split into a treatment arm, which was administered a single IV infusion of ketamine for 40 minutes, and a placebo arm, which received midazolam, an anesthetic also but in a different class.

Ketamine appears to be a safe and effective treatment option

Interviews with patients began after 24 hours, and patients were re-interviewed after seven days. At the first interview, the response rate in the treatment arm was 63.8 percent, compared to 28 percent in the placebo arm.

A week later, the response rate to the ketamine arm was still higher, at 45.7 percent, compared to 18.2 percent in the placebo arm.

Lead author James Murrough, MD, assistant professor of psychiatry at Mount Sinai, said that using midazolam as an active placebo allowed us to independently assess the antidepressant benefit of ketamine, excluding any anesthetic effects. Ketamine continues to show significant promise as a new treatment option for patients with severe and refractory forms of depression.

Dr. Murrough added, "We found that ketamine was safe and well-tolerated and that patients who demonstrated a rapid antidepressant effect after starting ketamine were able to maintain the response throughout the course of the study."

While the results are promising, Murrough said that future studies will need to be larger and placebo-controlled in order to support these findings and determine both the safety and efficacy profile of ketamine as a treatment for depression.

The research was presented at the American Psychiatric Association meeting in San Francisco. The findings should be considered preliminary until published in a peer-reviewed journal.

Source: MNT
Photo: Px Here

More Articles

According to a study by Sonya Deschênes of Concordia University and colleagues at Ryerson University in Toronto, and published in Cognitive...

There is no one cause for anxiety but several factors that contribute to its development. Scientists have broken them down into three parts: brain...

Agoraphobia is a disorder that develops when a person begins to avoid situations associated with anxiety. It arises from an anxiety condition that...

Parnate, known generically as tranylcypromine, is an antidepressant of the class known as monoamine oxidase inhibitors (MAOIs). It is usually...

If you're contemplating starting medication for an anxiety disorder, you no doubt have discovered that there are literally dozens of prescription...

More Articles

Much of our anxiety rests on assumptions that we have made. We assume the worst possible scenario will come true. We assume we know what others...

According to Oliver Robinson and colleagues at the University of Greenwich in London, young adults between the ages of 25 and 35 are vulnerable to...

Nardil, the brand name of the drug phenelzine, is the monoamine oxidase inhibitor (MAOI) most frequently prescribed for anxiety disorders. MAOIs...

Everyone has times when they're more anxious or depressed than usual, but psychologists have found that a person's "usual" level of anxiety or...

Folic acid, also known as vitamin B9, is a water-soluble vitamin that is necessary for healthy growth and development. There is significant...

A team of neuroscientists from the New School for Social Research in New York has announced that not only are the areas of the brain responsible...

Generalized anxiety disorder, or GAD, is an anxiety disorder characterized by chronic, excessive worry. People with GAD feel exaggerated anxiety...

I subscribe to the Psychotherapy Networker e-newsletter and just read a great article by Nancy Errebo, Psy. D., about using EMDR with a returning...

Norpramin is a brand name for the pharmaceutical desipramine, a tricyclic antidepressant which operates by inhibiting the reuptake of...

Do you have trouble putting your worries and anxieties aside as you go about your day? If you find that they’re always on your mind, you may want...

Vivactil (generic protriptyline hydrochloride) is a tricyclic antidepressant approved by the FDA to treat depression in adults (age 18 and over)....

Although people typically think of anxiety as a mental condition, it causes a number of physical symptoms. Severe anxiety, particularly...

Elavil (known generically as amitriptyline) is a tricyclic antidepressant that was approved by the FDA back in 1961 for treatment of major...

Generalized Anxiety Disorder, also known as (GAD), is a higher than normal level of anxiety that people experience day to day. It can fill ones...

The antidepressant doxepin (originally marketed by Pfizer under the brand name Sinequan) is a tricyclic antidepressant approved to treat anxiety...